Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice

In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and neurodegenerative disorders. Numerous studies suggest that targeting BDNF and its TrkB receptor could be a promising therapeutic strategy for the treatment of brain disorders. However, the devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazorla, Maxime, Jouvenceau, Anne, Rose, Christiane, Guilloux, Jean-Philippe, Pilon, Catherine, Dranovsky, Alex, Prémont, Joël
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841647/
https://www.ncbi.nlm.nih.gov/pubmed/20333308
http://dx.doi.org/10.1371/journal.pone.0009777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841647/
https://www.ncbi.nlm.nih.gov/pubmed/20333308
http://dx.doi.org/10.1371/journal.pone.0009777

Ejemplares similares